Herpesvirus Antiviral Resistance
Database


    • TOP

    Antimicrobial agents and chemotherapy


    Mutations:

    Mutant Gene Virus Reference
    E22STOP UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W153R UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    L193F UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    C218del UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    A269T UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    301-311del UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    V353E UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W362STOP UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    L426F UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    H142Y UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G143S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    G347D UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V355A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    S464F UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    D542E UL54 Human betaherpesvirus 5 Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E UL54 Human betaherpesvirus 5 Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E UL54 Human betaherpesvirus 5 Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A626V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P628L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A631G UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    M640R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S655L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S663N UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    F669L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S676G UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G678S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N685S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A688V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A693T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    Q697H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    V812L UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    Q868R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D870H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V873L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G874R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in884T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P887S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S897L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N898D UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    E899K UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V953A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A1012V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1020I UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T1108A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1116H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1122T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1133S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1146N UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1147S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1149T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1151del UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1153S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1156del UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1162L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1235T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    C25F UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V231A UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V231L UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    N232Y UL56 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    V236A UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V236L UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V236M UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    E237D UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L241P UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    T244K UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L257I UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    K258E UL56 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    F261C UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    F261L UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    Y321C UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325W UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    C325F UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325R UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325Y UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    L328V UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    M329T UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    A365S UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    R369G UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369M UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369S UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R396S UL56 Human betaherpesvirus 5 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    N320H UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    N329S UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    D344E UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    T350M UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    F342S UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342S UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K355del UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K355del UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    L405P UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    Q449K UL97 Human betaherpesvirus 5 Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    D456N UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    D456N UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    M460T UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    M460I UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460V UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    V466G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V466M UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    H469Y UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    A478V UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    C480R UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    C480R UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    H520Q UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    P521L UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    P521L UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    A588V UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    590-600del UL97 Human betaherpesvirus 5 Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001)
    Y617del UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    Y617del UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)